HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,008,595 | +284.8% | 26,403 | +473.2% | 0.00% | +300.0% |
| Q4 2022 | $262,082 | +52.4% | 4,606 | +18.0% | 0.00% | 0.0% |
| Q2 2022 | $172,000 | +27.4% | 3,902 | +15.6% | 0.00% | 0.0% |
| Q1 2022 | $135,000 | +3.1% | 3,374 | +3.9% | 0.00% | 0.0% |
| Q4 2021 | $131,000 | +11.0% | 3,247 | +12.0% | 0.00% | 0.0% |
| Q3 2021 | $118,000 | +0.9% | 2,898 | +12.1% | 0.00% | 0.0% |
| Q2 2021 | $117,000 | +8.3% | 2,585 | -0.1% | 0.00% | 0.0% |
| Q1 2021 | $108,000 | +30.1% | 2,588 | +32.4% | 0.00% | 0.0% |
| Q4 2020 | $83,000 | +84.4% | 1,955 | +15.0% | 0.00% | 0.0% |
| Q3 2020 | $45,000 | -4.3% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $47,000 | +80.8% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $26,000 | -10.3% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $29,000 | +7.4% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $27,000 | +8.0% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $25,000 | -19.4% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $31,000 | – | 1,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRAN CAPITAL MANAGEMENT, L.P. | 1,084,118 | $61,686,285 | 7.80% |
| SNYDER CAPITAL MANAGEMENT L P | 3,983,814 | $226,679,017 | 5.12% |
| First Light Asset Management, LLC | 923,119 | $52,525,471 | 4.88% |
| Redwood Investments, LLC | 441,809 | $25,138,932 | 3.37% |
| BERNZOTT CAPITAL ADVISORS | 444,728 | $25,305,023 | 3.27% |
| DOHENY ASSET MANAGEMENT /CA | 46,050 | $2,620 | 3.04% |
| Crawford Lake Capital Management, LLC | 42,171 | $2,399,530 | 2.75% |
| 2Xideas AG | 416,586 | $23,703,743 | 2.51% |
| Granite Investment Partners, LLC | 902,882 | $51,373,986 | 2.14% |
| HighMark Wealth Management LLC | 41,790 | $2,377,851 | 1.79% |